

CHEMBIO DIAGNOSTICS, INC.

Form 8-K

October 28, 2014

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 28, 2014 (October 27, 2014)

CHEMBIO DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction
of Incorporation)

0-30379

(Commission File Number)

88-0425691

(IRS Employer
Identification Number)

3661 Horseblock Road

Medford, NY 11763

(Address of principal executive offices)

631-924-1135

(Registrant's Telephone Number)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. REGULATION FD DISCLOSURE.

On October 27, 2014, the Company issued a press release entitled "Chembio Partners with Integrated BioTherapeutics, Inc. to Develop Point-of-Care Diagnostic Tests for Ebola and Febrile Illness". A copy of the press release is furnished herewith as Exhibit 99.1.

On October 28, 2014, the Company issued a press release entitled "Chembio Announces Agreements to Develop Point-of-Care Diagnostic Tests for Dengue Fever Virus and a Specific Type of Cancer". A copy of the press release is furnished herewith as Exhibit 99.2.

The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibits.

99.1 Press Release entitled "Chembio Partners with Integrated BioTherapeutics, Inc. to Develop Point-of-Care Diagnostic Tests for Ebola and Febrile Illness" dated October 27, 2014.

99.2 Press Release entitled "Chembio Announces Agreements to Develop Point-of-Care Diagnostic Tests for Dengue Fever Virus and a Specific Type of Cancer" dated October 28, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

October 28, 2014

Chembio Diagnostics, Inc.

By: /s/ John J. Sperzel III
John J. Sperzel III
Chief Executive Officer

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
99.1	Press Release entitled "Chembio Partners with Integrated BioTherapeutics, Inc. to Develop Point-of-Care Diagnostic Tests for Ebola and Febrile Illness" dated October 27, 2014.
99.2	Press Release entitled "Chembio Announces Agreements to Develop Point-of-Care Diagnostic Tests for Dengue Fever Virus and a Specific Type of Cancer" dated October 28, 2014.
